Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial
NCT07732218 on ClinicalTrials.gov · last registry update 2026-07-28
Finished 30 March 2023, after enrolling 95 people. Primary outcome, as filed: Change in Glycated hemoglobin. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Rehman Medical Institute - RMI
- Sponsor type
- Other
- Enrollment
- 95
- Started
- 2022-07-04
- Primary completion
- 2023-03-30 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Glycated hemoglobin
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.